Patent Covers Novel Method for Producing Photosensitizer-Inactivated Cancer Cell with Enhanced Immunogenicity for use in Cancer Immunotherapy

FORT COLLINS, Colo. , Sept. 9, 2025 /PRNewswire/ -- PhotonPharma, a biotechnology company developing next-generation cancer immunotherapies, today announced the issuance of U.S. Patent No. 12,280,039 B2 titled "Cancer Vaccine Compositions and Methods of Use Thereof." The patent, issued by the United States Patent and Trademark Office on April 22, 2025 , covers the Company's proprietary method for producing cancer immunotherapy products using photochemically-inactivated cancer cells that maintain immunogenic properties.

See Full Page